Alfadexx 2 mg/ml oldatos injekció lovak, szarvasmarhák, kecskék, sertések, kutyák és macskák számára A.U.V. Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

alfadexx 2 mg/ml oldatos injekció lovak, szarvasmarhák, kecskék, sertések, kutyák és macskák számára a.u.v.

alfasan nederland b.v. - dexametazon- nátrium-foszfát - oldatos injekció - dexamethasone - szarvasmarha, kecske, sertés, ló, kutya, macska

Pepaxti Európai Unió - magyar - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - myeloma multiplex - daganatellenes szerek - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Zynlonta Európai Unió - magyar - EMA (European Medicines Agency)

zynlonta

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - daganatellenes szerek - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Carvykti Európai Unió - magyar - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - myeloma multiplex - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.